Murlentamab |
Catalog No.GC72430 |
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2058047-65-5
Sample solution is provided at 25 µL, 10mM.
Murlentamab (20 mg/kg; i.v.; twice weekly for 4 weeks) inhibits tumor growth in mouse hepatocarcinoma PDX model in vivo[2].
References:
[1]. Prat M, et al. Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. Cancers (Basel). 2021 Apr 13;13(8):1845.
[2]. Barret JM, et al. The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer. Biology (Basel). 2021 Apr 7;10(4):305.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *